Is Major Neurocognitive Disorder The Same As Dementia?

Major neurocognitive disorder is the newer medical term for what was previously called dementia. The two terms refer to the same set of symptoms: a decline in thinking, memory, and daily function severe enough to interfere with independence. In 2013, the American Psychiatric Association updated its diagnostic manual (the DSM-5) and replaced “dementia” with “major neurocognitive disorder” to reduce stigma and improve diagnostic accuracy. So yes, for most practical purposes, they are the same condition under a different name.

Why Did the Name Change From Dementia to Major Neurocognitive Disorder?

The change happened for several reasons. First, the word “dementia” carries heavy stigma. Many people associate it with a total loss of self or a hopeless decline. The new term focuses on the cognitive symptoms themselves rather than the social label.

Second, the old term was too narrow. Dementia implied memory loss as the main problem. But many conditions cause cognitive decline without memory being the first or worst symptom. For example, frontotemporal degeneration often hits personality and language before memory. The term “major neurocognitive disorder” covers a wider range of cognitive problems.

Third, the change allows for a milder category called “mild neurocognitive disorder.” This catches people in the early stages when symptoms are noticeable but not disabling. Under the old system, these people often got no diagnosis at all or were told they had “mild cognitive impairment” — a term that never fit neatly into the dementia framework.

Is Major Neurocognitive Disorder the Same as Dementia in Clinical Practice?

In most doctors’ offices and hospitals, the terms are used interchangeably. You will still hear neurologists say “dementia” when talking to patients because the general public knows that word. But in medical records and research papers, “major neurocognitive disorder” is now the standard term.

The diagnostic criteria are essentially identical. For both diagnoses, a person must show significant decline in at least one cognitive domain such as memory, attention, language, or executive function. That decline must interfere with daily activities like managing finances, driving, or taking medications. And it must not be explained by delirium or another mental health condition.

One important difference: the DSM-5 criteria for major neurocognitive disorder require objective evidence of decline through standardized testing or clinical assessment. Some older dementia diagnoses relied more on a doctor’s subjective impression. So the new criteria are actually more rigorous, not looser.

What Conditions Fall Under Major Neurocognitive Disorder?

Major neurocognitive disorder is an umbrella term. It covers multiple underlying diseases, just like “dementia” did. The most common causes include:

• Alzheimer’s disease — the most common cause, accounting for 60-80% of cases. Memory loss is typically the first symptom.
• Vascular cognitive impairment — caused by reduced blood flow to the brain from strokes or small vessel disease. Symptoms vary depending on which brain areas are affected.
• Lewy body disease — involves protein clumps called Lewy bodies. Hallucinations, movement problems, and fluctuating alertness are common.
• Frontotemporal degeneration — affects the front and sides of the brain. Personality changes, language problems, and poor judgment often appear before memory loss.
• Parkinson’s disease dementia — develops in many people with advanced Parkinson’s disease.
• Mixed dementia — more common than once thought. Many older adults have brain changes from both Alzheimer’s and vascular disease at the same time.

Each type has its own pattern of progression and treatment options. Knowing which one a person has matters for planning care and managing symptoms.

How Is Major Neurocognitive Disorder Diagnosed?

Diagnosis requires a thorough evaluation. No single blood test or brain scan can confirm it. Doctors typically start with a detailed history from the patient and a family member. The family member’s input is often more revealing because people with cognitive decline may not recognize their own symptoms.

The evaluation usually includes cognitive testing. The Montreal Cognitive Assessment (MoCA) is a common screening tool. It takes about 10 minutes and tests memory, attention, language, and visuospatial skills. A score below 26 out of 30 suggests possible problems, but this is just a screening, not a diagnosis.

Brain imaging is often part of the workup. A CT or MRI scan can show shrinkage in specific brain regions, evidence of past strokes, or other structural problems. In some cases, a PET scan can detect Alzheimer’s-related protein deposits.

Blood work is done to rule out reversible causes. Thyroid problems, vitamin B12 deficiency, and certain infections can mimic dementia. A 2019 study in JAMA found that about 9% of people referred for dementia evaluation had a potentially reversible condition. These are rare but worth checking for.

What Does Treatment Look Like for Major Neurocognitive Disorder?

Treatment depends on the underlying cause. For Alzheimer’s disease, there are medications that can slow symptom progression for a time. Cholinesterase inhibitors like donepezil (Aricept) and rivastigmine (Exelon) are the main options. A newer class of drugs called anti-amyloid antibodies, such as lecanemab, was approved by the FDA in 2023 for early Alzheimer’s. These drugs remove amyloid plaques from the brain and modestly slow decline.

For vascular cognitive impairment, the priority is controlling risk factors. This means managing blood pressure, diabetes, and cholesterol. Preventing further strokes is the most effective way to slow progression.

For Lewy body dementia, medications for movement symptoms and hallucinations can help. But these patients are very sensitive to antipsychotic drugs, which can cause severe side effects. Careful dosing is critical.

Non-drug approaches matter just as much. Structured routines, cognitive stimulation, physical exercise, and social engagement all help maintain function longer. A 2018 study in the Lancet found that addressing 12 modifiable risk factors — including hearing loss, smoking, and depression — could prevent or delay up to 40% of dementia cases.

Common Misconceptions About Major Neurocognitive Disorder

Misconception: It is the same as normal aging. Some forgetfulness is normal with age. Losing keys is normal. Forgetting what keys are used for is not. Major neurocognitive disorder involves a clear decline from a person’s previous level of function, not just age-related slowing.

Misconception: Nothing can be done after diagnosis. This is false. While most causes are not reversible, treatment can slow progression, manage symptoms, and improve quality of life. Planning for legal, financial, and care needs early gives people more control over their future.

Misconception: Memory loss is always the first symptom. In Alzheimer’s, yes, usually. But in frontotemporal degeneration, personality changes or language problems often come first. In vascular dementia, symptoms depend on where strokes occur. Some people never have significant memory problems until late in the disease.

Misconception: Supplements can prevent or reverse it. There is no clinical evidence that any supplement, vitamin, or herbal product can prevent or reverse major neurocognitive disorder. Ginkgo biloba, vitamin E, and coconut oil have all been studied with disappointing results. The best evidence for prevention points to lifestyle factors: exercise, blood pressure control, hearing treatment, and not smoking.

When Should Someone See a Doctor?

The National Institute on Aging recommends seeing a doctor if cognitive changes interfere with daily life for more than six months. Warning signs include getting lost in familiar places, trouble handling money, repeating questions, and personality changes that worry family members.

Early diagnosis has real benefits. It gives people time to plan, participate in treatment decisions, and enroll in clinical trials if they choose. It also rules out treatable causes that could be mistaken for dementia.

Many people delay evaluation because they fear the diagnosis. That is understandable. But knowing what you are dealing with is almost always better than wondering. Most families say they wish they had gotten answers sooner.